Dalpiciclib added to fulvestrant (Faslodex) was found to significantly prolong progression-free survival compared with fulvestrant monotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Just 2 of 41 nutritionists interviewed reported using a validated screener, while 4 others said they use other tools, such as screening questions developed by other organizations, results show.
Ixekizumab (Taltz) is indicated for the treatment of conditions such as plaque psoriasis, psoriatic arthritis, active ankylosing spondylitis, and non-radiographic axial spondyloarthritis.
The continued upward trend in testing and vaccination demand, coupled with staffing shortages, technology gaps, and never-ending to-do lists, exacerbates spikes in patient volume and workload for pharmacy professionals.
FDA to evaluate adagrasib for the treatment of patients with non–small cell lung cancer with tumors that have a KRAS G12C mutation.
Results of CheckMate-9ER trial in first-line advanced renal cell carcinoma will be featured in 2 poster presentations at the American Society of Clinical Oncology 2022 Genitourinary Cancers Symposium.
The common-weight loss plan synergizes with chemotherapy to triple survival time compared with the treatment alone in rigorous mouse models of PDAC, the analysis shows.
Niraparib is associated with increased progression-free survival, regardless of the presence or absence of BRCA gene mutations.
The use of these services in oncology is likely here to stay.
The lingering effects of the COVID-19 pandemic, including supply concerns and staffing shortages, have made technological solutions become more crucial.
A variety of drugs from several medication classes are under investigation.
New composite pharmacy adherence measure is a major step in developing standard pharmacy performance measures focused on improving patient care.
Ixazomib (Ninlaro, Takeda) has been found to improve survival in patients with multiple myeloma who have not undergone autologous stem cell transplant.
Diroximel fumarate (Vumerity) is indicated for the treatment of relapsing forms of multiple sclerosis.
Larotrectinib was the first drug to receive accelerated FDA approval for patients of all ages based on a common molecular marker, independent of tissue origin for targeted therapy.
Applying these findings in practice could improve clinicians’ ability to offer truly personalized cancer therapy by enabling consideration of toxicity along with other data predicting patients’ responses.
Selinexor demonstrated a 37% increase in probability that patients treated with the drug will be in remission at 12 months.
The uncommon disease shares features of both lymphoma and myeloma.
The results of a pilot program investigating the efficacy of remote patient monitoring for patients with cancer showed that it helped to keep high-risk individuals out of the hospital.
Communication, flexibility, and virtual solutions will remain key as the COVID-19 pandemic continues.
Effective specialty pharmacies learn to meet the changing needs of patients and stakeholders.
Trametinib emerged as a novel therapeutic approach for low-grade serous carcinoma due to a high prevalence of activating mutations in the mitogen-activated protein kinase signaling pathway.
Patients with rheumatoid arthritis taking at least 3 targeted therapies were found to have a greater risk of developing herpes zoster.
New study results show that the drugs, which block estrogen production, are more effective for premenopausal and postmenopausal women.
Ned Milenkovich, PharmD, JD, licensed pharmacist and principal at Much Law, PC, discusses the announcement of the Mark Cuban Cost Plus Drug Company, which will, in some cases, offer expensive medication at a drastically lower price without insurance.
Christopher Mast, MD, vice president of clinical informatics at Epic, explains his outlook for the future in the field of oncology in light of the ongoing delays in cancer screenings rates.
Patients receiving brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in the frontline setting had a 41% reduction in the risk of death.
Christopher Mast, MD, vice president of clinical informatics at Epic, explains the level to which cancer screening rates would need to rise to meet pre-pandemic rates.
Results from a clinical trial led by investigators at the National Cancer Institute show that 28 of 42 women with tumors generated a reaction.
Christopher Mast, MD, vice president of clinical informatics at Epic, discusses research that showed that cancer screening rates in 2021 rebounded from the low rates at the start of the pandemic, but not significantly.
